The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Psychedelics represent one of the most promising classes of experimental medicines for the
treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and …

Abstract (R, S)-ketamine elicits rapid-acting and sustained antidepressant actions in
treatment-resistant patients with depression.(R)-ketamine produces longer-lasting …

Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used
as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine …

Objective: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces
opioid system activation. The objective of this study was to determine whether opioid …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …

Background Over the past 2 decades, the use of intravenous ketamine infusions as a
treatment for chronic pain has increased dramatically, with wide variation in patient …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …